JAK2
JAK2 (Janus kinase 2) is a non-receptor tyrosine kinase that plays a critical role in cellular signaling and immune regulation.
JAK2 (Janus kinase 2) is a non-receptor tyrosine kinase that plays a critical role in cellular signaling and immune regulation. As a member of the Janus kinase family, JAK2 functions as a key signal transducer that associates with cytokine receptors and phosphorylates downstream targets, particularly the Signal Transducer and Activator of Transcription (STAT) proteins. The protein is essential for mediating signaling from hematopoietic cytokine receptors involved in immune cell development, including effects on macrophages, dendritic cells, and natural killer cells. JAK2 has emerged as an important therapeutic target for various disease conditions, particularly inflammatory disorders, malignancies, and autoimmune diseases such as rheumatoid arthritis. Additionally, activating mutations in the JAK2 gene are associated with myeloproliferative neoplasms, including polycythaemia vera, a clonal disease characterized by increased thromboembolic risk.
The JAK2/STAT signaling cascade represents one of the most significant intracellular communication pathways in immunology and inflammation. Upon cytokine binding to cell surface receptors, JAK2 becomes activated and phosphorylates both the receptor and downstream STAT proteins, which then translocate to the nucleus to regulate gene transcription. This pathway controls inflammatory responses through modulation of pro-inflammatory mediators including tumor necrosis factor-α (Tnf-α) and Interleukin-6 (IL-6), making JAK2 inhibition an attractive therapeutic strategy for conditions characterized by excessive inflammation or pathologic immune activation.
Where the papers sit
14 papers from the last 6 months study JAK2 directly · updated from PubMed 13 Nov 2026
Study type 2 clinical trials · 3 human data · 8 preclinical · 1 unclassified
Themes 3 themes · 1 new direction
-
JAK-STAT Signaling Modulation
JAK-STAT signaling is being modulated across cancer, infection, inflammation, and tissue injury rather than pursued as one disease program. Inhibitory approaches recur in IL-6-dependent lymphoma, diabetic cardiomyopathy, influenza, ulcerative colitis, neuropathic pain, and RAGE-linked oncogenic signaling. Natural products such as sinomenine, hydrogen sulfide, Ganhuangcao, and Callistephus A dominate several studies, while proanthocyanidin derivatives instead activate JAK2 to limit chemotherapy-induced myelosuppression. The evidence remains mainly mechanistic or preclinical, leaving disease-selective efficacy and pathway toxicity open.
8 papers · 57.1%
-
JAK Inhibition in Graft-Versus-Host Disease
JAK1/2 inhibition is moving from treatment of established graft-versus-host disease toward prevention after haploidentical transplantation. Low-dose ruxolitinib is being tested in a multicentre study for prevention, while baricitinib has entered phase 1/2 evaluation for refractory chronic disease. Cumulative incidence, neutropenia, and transplant-related safety are central endpoints. The open question is whether early immunomodulation can reduce GVHD without excess immunosuppression or cytopenia.
2 papers · 14.3%
-
Others — Inflammatory and Myeloproliferative Disease
Dermatitis and psoriasis studies pursue topical or transdermal anti-inflammatory treatment, including ruxolitinib cream, sulforaphane nanoparticles, and JAK/HDAC dual inhibitors. HDAC6 inhibition and compound 11e point to kinase and epigenetic drug design, while metabolomics seeks disease-specific signatures in polycythaemia vera. The set therefore links inflammatory skin disease with myeloproliferative-disease diagnosis rather than a single therapeutic program. No common clinical direction is established.
4 papers · 28.6%
JAK2 is presented as a therapeutic activator for restoring hematopoiesis, not merely as a pathogenic kinase to inhibit
The chemotherapy-induced myelosuppression model and Type-A proanthocyanidin derivative 32 show that direct JAK2 activation can be beneficial: compound 32 preferentially binds the JH2 pseudokinase domain, activates JAK2/STAT3 signaling, and promotes hematopoietic recovery in cells and mice after carboplatin injury 42593935Aug. This departs from the set’s prevailing use of JAK2 as an inflammatory or oncogenic pathway to suppress, adding a restorative, positive-regulation role and directing therapeutic development toward JAK2 activators.
Papers
The 14 papers from the last 6 months that study JAK2 directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
JAK-STAT Signaling Modulation (8)
- Structure-guided discovery of a dual JAK2/RAGE modulator reveals a computationally driven strategy for targeting convergent oncogenic signaling in renal cell carcinoma. Journal of computer-aided molecular design · 15 Oct 2026 PMID 42878945
- Discovery of CDK8/19 inhibitors as lead compounds for IL-6-dependent lymphoma enabled by the formal synthesis of cortistatin A. Science advances · 4 Sept 2026 PMID 42696577
- Design and Synthesis of Type-A Proanthocyanidin Derivatives as JAK2 Activators to Protect against Chemotherapy-Induced Myelosuppression. Journal of medicinal chemistry · 13 Aug 2026 PMID 42593935
- Sinomenine Liposomes Alleviate Neuropathic Pain in a Spared Nerve Injury Model by Regulating Astrocyte Reactivity Associated with Inhibition of the JAK2/STAT3 Pathway. Neurochemical research · 13 Aug 2026 PMID 42593631
- Callistephus A from Callistephus chinensis Alleviates DSS-Induced Ulcerative Colitis and Gut-liver Axis Disruption by Targeting the JAK2/STAT1 Pathway and Remodeling Gut Microbiota. Journal of ethnopharmacology · 20 Jul 2026 PMID 42476206
- Type II JAK2 Inhibitor Gets Off to a Strong Start. Cancer discovery · 1 Jul 2026 PMID 42381481
- Network pharmacology and experimental validation reveal inhibition of the JAK2/STAT3 pathway by hydrogen sulfide in diabetic cardiomyopathy. International immunopharmacology · 8 Jun 2026 PMID 42259239
- Chinese authentic herbal medicine Ganhuangcao from Southwest China mitigates influenza virus infection by inhibiting the host JAK2/STAT1 signaling pathway. Phytomedicine : international journal of phytotherapy and phytopharmacology · 20 May 2026 PMID 42160896
JAK Inhibition in Graft-Versus-Host Disease (2)
- Low-dose ruxolitinib for graft-versus-host disease prevention in haploidentical haematopoietic stem-cell transplantation: a multicentre, open-label, randomised, controlled, phase 3 trial. The Lancet. Haematology · 30 Jul 2026 PMID 42532067
- Baricitinib for refractory chronic graft-versus-host disease: results of a phase 1/2 study. Blood advances · 27 May 2026 PMID 42200447
Others — Inflammatory and Myeloproliferative Disease (4)
- Design, Synthesis, and Biological Evaluation of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Psoriasis. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018590
- Real-world clinical experience with ruxolitinib cream versus systemic therapies in patients with moderate atopic dermatitis in the United States. The Journal of dermatological treatment · 7 Sept 2026 PMID 42704072
- LC-QQQ serum metabolomics reveals disease-specific metabolic signatures and diagnostic metabolite panels distinguishing polycythaemia vera from secondary polycythaemia. Metabolomics : Official journal of the Metabolomic Society · 3 Jul 2026 PMID 42397475
- Study on transdermal delivery system of sulforaphane chitosan nanoparticles based on methacryloylated chitosan microneedles: application in the treatment of irritant contact dermatitis. International journal of pharmaceutics · 14 Jun 2026 PMID 42289208
By study type
Clinical trials (2)
- Low-dose ruxolitinib for graft-versus-host disease prevention in haploidentical haematopoietic stem-cell transplantation: a multicentre, open-label, randomised, controlled, phase 3 trial. The Lancet. Haematology · 30 Jul 2026 PMID 42532067
- Baricitinib for refractory chronic graft-versus-host disease: results of a phase 1/2 study. Blood advances · 27 May 2026 PMID 42200447
Human data, design not indexed (3)
- Real-world clinical experience with ruxolitinib cream versus systemic therapies in patients with moderate atopic dermatitis in the United States. The Journal of dermatological treatment · 7 Sept 2026 PMID 42704072
- LC-QQQ serum metabolomics reveals disease-specific metabolic signatures and diagnostic metabolite panels distinguishing polycythaemia vera from secondary polycythaemia. Metabolomics : Official journal of the Metabolomic Society · 3 Jul 2026 PMID 42397475
- Type II JAK2 Inhibitor Gets Off to a Strong Start. Cancer discovery · 1 Jul 2026 PMID 42381481
Preclinical: animal, cell and lab studies (8)
- Design, Synthesis, and Biological Evaluation of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Psoriasis. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018590
- Structure-guided discovery of a dual JAK2/RAGE modulator reveals a computationally driven strategy for targeting convergent oncogenic signaling in renal cell carcinoma. Journal of computer-aided molecular design · 15 Oct 2026 PMID 42878945
- Discovery of CDK8/19 inhibitors as lead compounds for IL-6-dependent lymphoma enabled by the formal synthesis of cortistatin A. Science advances · 4 Sept 2026 PMID 42696577
- Design and Synthesis of Type-A Proanthocyanidin Derivatives as JAK2 Activators to Protect against Chemotherapy-Induced Myelosuppression. Journal of medicinal chemistry · 13 Aug 2026 PMID 42593935
- Sinomenine Liposomes Alleviate Neuropathic Pain in a Spared Nerve Injury Model by Regulating Astrocyte Reactivity Associated with Inhibition of the JAK2/STAT3 Pathway. Neurochemical research · 13 Aug 2026 PMID 42593631
- Study on transdermal delivery system of sulforaphane chitosan nanoparticles based on methacryloylated chitosan microneedles: application in the treatment of irritant contact dermatitis. International journal of pharmaceutics · 14 Jun 2026 PMID 42289208
- Network pharmacology and experimental validation reveal inhibition of the JAK2/STAT3 pathway by hydrogen sulfide in diabetic cardiomyopathy. International immunopharmacology · 8 Jun 2026 PMID 42259239
- Chinese authentic herbal medicine Ganhuangcao from Southwest China mitigates influenza virus infection by inhibiting the host JAK2/STAT1 signaling pathway. Phytomedicine : international journal of phytotherapy and phytopharmacology · 20 May 2026 PMID 42160896
Unclassified: not yet indexed with MeSH (1)
- Callistephus A from Callistephus chinensis Alleviates DSS-Induced Ulcerative Colitis and Gut-liver Axis Disruption by Targeting the JAK2/STAT1 Pathway and Remodeling Gut Microbiota. Journal of ethnopharmacology · 20 Jul 2026 PMID 42476206
Written from 14 PubMed abstracts, each one listed by PMID above. Published: 2026-07-26. Last written: 2026-08-27 by GPT. Drafted by language models from published abstracts; not medical advice.